Skip to Content

Myocard-DX (dopamine) Disease Interactions

There are 5 disease interactions with Myocard-DX (dopamine):

Major

Dopamine (Includes Myocard-DX) ↔ Arrhythmias

Severe Potential Hazard, High plausibility

Applies to: Arrhythmias

The use of dopamine is contraindicated in patients with uncorrected tachyarrhythmias or ventricular fibrillation. Dopamine exerts an agonistic action on the beta receptors of the heart which may lead to an increase in heart rate, atrial fibrillation, enhanced A-V conduction, ventricular ectopy, and arrhythmias.

References

  1. Gelfman DM, Ornato JP, Gonzalez ER "Dopamine-induced increase in atrioventricular conduction in atrial fibrillation-flutter." Clin Cardiol 10 (1987): 671-3
  2. "Product Information. Intropin (dopamine)." DuPont Pharmaceuticals, Wilmington, DE.
  3. Tisdale JE, Patel RV, Webb Cr, Borzak S, Zarowitz BJ "Proarrhythmic effects of intravenous vasopressors." Ann Pharmacother 29 (1995): 269-81
Major

Dopamine (Includes Myocard-DX) ↔ Dehydration

Severe Potential Hazard, High plausibility

Applies to: Dehydration

The use of dopamine has been infrequently associated with significant hypotension especially in dehydrated patients secondary to beta-2 mediated vasodilation. Hypovolemia should be corrected before administering dopamine. Blood pressure and ECG should be monitored at regular intervals. Monitoring of cardiac output and pulmonary wedge pressure is recommended.

References

  1. "Product Information. Intropin (dopamine)." DuPont Pharmaceuticals, Wilmington, DE.
Major

Dopamine (Includes Myocard-DX) ↔ Ischemic Heart Disease

Severe Potential Hazard, High plausibility

Applies to: Ischemic Heart Disease

The use of dopamine may worsen ischemic heart disease. The stimulation of cardiac beta receptors may aggravate ischemic heart disease. Therapy with dopamine should be administered cautiously in patients with ischemic heart disease. Monitoring of ECG, blood pressure, urine flow, and cardiac output is recommended.

References

  1. "Product Information. Intropin (dopamine)." DuPont Pharmaceuticals, Wilmington, DE.
  2. Ebels T, van der Heide JN "Dopamine-induced ischaemia ." Lancet 2 (1977): 762
Major

Dopamine (Includes Myocard-DX) ↔ Peripheral Vascular Disease

Severe Potential Hazard, High plausibility

Applies to: Peripheral Arterial Disease

The vasoconstrictive actions of dopamine may aggravate occlusive vascular disease (atherosclerosis, arterial embolism, Raynaud's disease, cold injury, diabetic endarteritis, or Buerger's disease). Therapy with dopamine should be administered cautiously in patients with occlusive vascular disease. Patients should be monitored for decreased circulation to the extremities (change in color or temperature of the skin).

References

  1. Ross M "Dopamine-induced localized cutaneous vasoconstriction and piloerection ." Arch Dermatol 127 (1991): 586-7
  2. Stetson JB, Reading GP "Avoidance of vascular complications associated with the use of dopamine." Can Anaesth Soc J 24 (1977): 727-33
  3. Julka NK, Nora JR "Letter: Gangrene aggravation after use of dopamine." JAMA 235 (1976): 2812-3
View all 8 references
Major

Dopamine (Includes Myocard-DX) ↔ Pheochromocytoma

Severe Potential Hazard, High plausibility

Applies to: Pheochromocytoma

The use of dopamine is contraindicated in patients with pheochromocytoma. The catecholamine effects of dopamine may aggravate this condition.

References

  1. "Product Information. Intropin (dopamine)." DuPont Pharmaceuticals, Wilmington, DE.

Myocard-DX (dopamine) drug Interactions

There are 306 drug interactions with Myocard-DX (dopamine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide